References

AAHRPP (Association for the Accreditation of Human Research Protection Programs). 2002a. Final Standards. [Online]. Available: http://www.aahrpp.org/images/standards.PDF [accessed February 28, 2002].

AAHRPP. 2002b. Accreditation Principles. [Online]. Available: http://www.aahrpp.org/accreditation_principles.htm [accessed February 28, 2002].

AAHRPP. 2002c. Accreditation Step-by-Step. [Online]. Available: http://www.aahrpp.org/steps.htm [accessed May 7, 2002].

AAHRPP. 2002d. Fees. [Online]. Available: http://www.aahrpp.org/fees.htm [accessed February 28, 2002].

AAMC (Association of American Medical Colleges). 1990. Guidelines for Dealing With Faculty Conflicts of Commitment and Conflicts of Interest in Research. [Online]. Available: http://www.aamc.org/research/dbr/coi.htm [accessed May 23, 2001].

AAMC. 2001. Protecting Subjects, Preserving Trust, Promoting Progress—Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research. Washington, DC: AAMC.

AAU (Association of American Universities) Task Force on Research Accountability. 2001. Report on Individual and Institutional Financial Conflict of Interest. Washington, DC: AAU.

AAUP (American Association of University Professors). 2001. Protecting Human Beings: Institutional Review Boards and Social Science Research. Academe 87(3):55–67.

ACHRE (Advisory Committee on Human Radiation Experiments). 1995. Final Report: Advisory Committee on Human Radiation Experiments. Washington, DC: Government Printing Office.

ACRP (Association of Clinical Research Professionals). 2001. Code of Ethics. [Online]. Available: http://www.acrpnet.org/ethics/index.html [accessed December 28, 2001].

Agre P, Kurtz RC, Krauss BJ. 1994. A Randomized Trial Using Videotape to Present Consent Information for Colonoscopy. Gastrointestinal Endoscopy 40(3):271–276.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants References AAHRPP (Association for the Accreditation of Human Research Protection Programs). 2002a. Final Standards. [Online]. Available: http://www.aahrpp.org/images/standards.PDF [accessed February 28, 2002]. AAHRPP. 2002b. Accreditation Principles. [Online]. Available: http://www.aahrpp.org/accreditation_principles.htm [accessed February 28, 2002]. AAHRPP. 2002c. Accreditation Step-by-Step. [Online]. Available: http://www.aahrpp.org/steps.htm [accessed May 7, 2002]. AAHRPP. 2002d. Fees. [Online]. Available: http://www.aahrpp.org/fees.htm [accessed February 28, 2002]. AAMC (Association of American Medical Colleges). 1990. Guidelines for Dealing With Faculty Conflicts of Commitment and Conflicts of Interest in Research. [Online]. Available: http://www.aamc.org/research/dbr/coi.htm [accessed May 23, 2001]. AAMC. 2001. Protecting Subjects, Preserving Trust, Promoting Progress—Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research. Washington, DC: AAMC. AAU (Association of American Universities) Task Force on Research Accountability. 2001. Report on Individual and Institutional Financial Conflict of Interest. Washington, DC: AAU. AAUP (American Association of University Professors). 2001. Protecting Human Beings: Institutional Review Boards and Social Science Research. Academe 87(3):55–67. ACHRE (Advisory Committee on Human Radiation Experiments). 1995. Final Report: Advisory Committee on Human Radiation Experiments. Washington, DC: Government Printing Office. ACRP (Association of Clinical Research Professionals). 2001. Code of Ethics. [Online]. Available: http://www.acrpnet.org/ethics/index.html [accessed December 28, 2001]. Agre P, Kurtz RC, Krauss BJ. 1994. A Randomized Trial Using Videotape to Present Consent Information for Colonoscopy. Gastrointestinal Endoscopy 40(3):271–276.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Alberti KG. 2000. Multicentre research ethics committees: Has the cure been worse than the disease? No, but idiosyncracies and obstructions to good research must be removed. British Medical Journal 320(7243):1157–1158. Altman D. 2002. Poor-Quality Medical Research: What Can Journals Do? JAMA 287(21):2869–2871. Amdur RJ. 2000. Improving the Protection of Human Research Subjects. Academic Medicine 75(7):718–720. Andejeski et al. 2002. Quantitative impact of including consumers in the scientific review of breast cancer research proposals. Journal of Women’s Health and Gender-Based Medicine 11(4):351–360. Anderson D, Costa I, Dickersin K. Forthcoming. Building Trials Central, an online register of clinical trials registers. Controlled Clinical Trials. Angell M. 2000. Presentation at the August 15-16, 2000, Conference on Human Subject Protection and Financial Conflicts of Interest, National Institutes of Health, Bethesda, MD. Annas GJ. 1991. Ethics Committees: From Ethical Comfort to Ethical Cover. Hastings Center Report 21(3):18–21. Annas GJ and Grodin M. 1992. The Nazi Doctors and the Nuremberg Code: Human Rights in Human Experimentation. Oxford: Oxford University Press. Annas, et al. 1977. Compensation for Harm: An Additional Protection for Human Subjects. In: Informed Consent: The Subject’s Dilemma. Cambridge, MA: Ballinger Publishing Company. Pp. 257–277. Antman EM, et al. 1992. A Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical Experts: Treatments for Myocardial Infarction. JAMA 268(2):240–247. Appelbaum PS, Roth LH, Lidz C. 1982. The therapeutic misconception: Informed consent in psychiatric research. International Journal of Law and Psychiatry 5(3-4):319–329. Argetsinger A. 2001, October 27. Smallpox Vaccine Studies Swamped with Volunteers. The Washington Post. p. B1. ASGT (American Society of Gene Therapy). 2000. Policy of the American Society of Gene Therapy on Financial Conflict of Interest in Clinical Research. [Online]. Available: http://www.asgt.org/policy/index.html [accessed December 28, 2001]. Atkinson HG. 2000. Decision-making dialogue. Health News 6(2):4–5. Barnbaum D. 2002. Making More Sense of “Minimal Risk.” IRB: Ethics and Human Research 24(3):10–13. Bastian H. 1994. The Power of Sharing Knowledge: Consumer Participation in the Cochrane Collaboration. [Online]. Available: http://www.cochraneconsumer.com/p_Involve.asp [accessed August 14, 2002]. Batt S. 1994. Patient No More: The Politics of Breast Cancer. Canada: Gynergy Books. Bazell R. 1998. HER-2: The Making of Herception, a Revolutionary Treatment for Breast Cancer. New York City: Random House. Beecher HK. 1966. Ethics and Clinical Research. New England Journal of Medicine 274(24): 1354–1360. Bell J, et al. 1998. Prepared for the Office of Extramural Research, NIH. Evaluation of NIH Implementation of Section 491 of the Public Health Service Act, Mandating a Program of Protection for Research Subjects. Alexandria, VA: James Bell and Associates. Benson PR, et al. 1988. Information Disclosure, Subject Understanding, and Informed Consent in Psychiatric Research. Law and Human Behavior 12(4):455–475. Berwick DM. 1990. Peer review and quality management: Are they compatible. Quality Review Bulletin 16(7):246–251. Blumenstyk G. 2002, January 11. Crusader for the Rights of Research Volunteers. The Chronicle of Higher Education. p. A34.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Blumenthal D. 2001. Financial Conflict of Interest in Academic Medicine: How Much and Who? Presentation at the October 16, 2001, annual meeting of the Institute of Medicine, Washington, DC. Bodenheimer T. 2001. Industry, Academia, Investigator: Managing the Relationships: What is the impact on science? Presentation at the October 16, 2001, annual meeting of the Institute of Medicine, Washington, DC. Bohaychuck W, et al. 1998. Ethics Committee and IRB Audit Results. Good Clinical Practice. November 1998:46–55. Briefer French J. 2002. Presentation at the March 26, 2002, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Briguglio J, et al. 1995. Development of a Model Angiography Informed Consent Form Based on a Multiinstitutional Survey of Current Forms. Journal of Vascular and Interventional Radiology 6(6):971–978. Brookmeyer R and Blades N. 2002. Prevention of Inhalational Anthrax in U.S. Outbreak. Science 295:1861. CAC (Citizen Advocacy Center). 1994. Public Representation on Health Care Regulatory, Governing, and Oversight Bodies: Strategies for Success: Proceedings of a Workshop Convened by The Citizen Advocacy Center. Preface, Executive Summary, Introduction, and Keynote. Washington, DC: The Citizen Advocacy Center. CAC. 2002. About CAC. [Online]. Available: http://www.cacenter.org/about.htm [accessed August 28, 2002]. Centerwatch. 2001. Background Information on Clinical Research. [Online]. Available: http://www.centerwatch.com/patient/backgrnd.html [accessed July 25, 2002]. Chalmers TC. 1977. Randomize the first patient. New England Journal of Medicine 296:107. Cho MK, et al. 2000. Policies on Faculty Conflicts of Interest at U.S. Universities. JAMA 284(17):2203–2208. Cho M, Billings P. 1997. Conflict of Interest and Institutional Review Boards. Journal of Investigative Medicine 45(4):154–159. Churchill LR, et al. 1998. Genetic Research as Therapy: Implications of “Gene Therapy” for Informed Consent. Journal of Law and Medical Ethics 26:38–47. CIOMS (Council for International Organizations of Medical Sciences). 1993. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS. CIOMS. 1982. Bankowski Z and Howard Jones N, eds. Human Experimentation and Medical Ethics. Geneva: CIOMS. Clinton WJ. 1997. Strengthened Protections for Human Subjects of Classified Research. Federal Register 62(92):26369–26372. Cohen J. 1994. Clinical Trial Monitoring: Hit or Miss? Science 264:1536. Cohen P. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Connolly C, Goldstein A. 2001, December 20. Anthrax Vaccine Plan Sows Confusion: DC Advises Workers Against Treatment. The Washington Post. p. A1. Cooke RA and Tannenbaum AS. 1978. A Survey of Institutional Review Boards and Research Involving Human Subjects. In: National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Appendix to Report and Recommendations: Institutional Review Boards. Washington, DC: Department of Health, Education, and Welfare. Coulter A. 1999. Shared Decision-Making: A Summary and Future Issues. In: Maslin A. Breast Cancer: Sharing the Decisions. Oxford: Oxford University Press. Pp. 99–108. Council of Europe Publishing, ed. 1997. Convention on Human Rights and Biomedicine (Oviedo, 4.IV.1997). Europe: Council of Europe Publishing. Council on Ethical and Judicial Affairs, AMA (American Medical Association). 2000. Code of Medical Ethics: Current Opinions. Chicago, IL: AMA.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Cowdry, R. 2001. Presentation at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. CPMP Working Party on Efficacy of Medicinal Products. 1995. Biostatistical Methodology in Clinical Trials in Applications for Marketing Authorizations for Medicinal Products. Note for Guidance III/3630/92-EN. Statistics in Medicine 14:1659–1682. Crocco A, Villasis-Keever M, Jadad A. 2002. Analysis of Cases of Harm Associated with Use of Health Information on the Internet . JAMA 287(21):2869–2871. Daugherty C, et al. 1995. Perceptions of cancer patients and their physicians involved in phase I trials. Journal of Clinical Oncology 13(5):1062–1072. Davidoff F, DeAngelis CD, Drazen JM, et al. 2001. Sponsorship, Authorship, and Accountability. JAMA 286(10):1232–1234. Davidson, D. 2002. Statement on HHS’ Proposed Changes to the Medical Privacy Rules. [Online]. Available: http://www.aha.org/info/releasedisplay.asp?passreleaseid=402 [accessed May 6, 2002]. Davis DA, et al. 1995. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 274(9):700–705. Davis DA and Taylor-Vaisey AL. 1997. Translating guidelines into practice: A systematic review of theoretical concepts, practical experience, and research evidence in the adoption of clinical practice guidelines. Canadian Medical Association Journal 157(4):408–416. Day SJ, Altman DG. 2000. Blinding in clinical trials and other studies. British Medical Journal 321:504. Dembner A. 2002, August 12. Lawsuits Target Medical Research. The Boston Globe. p. A1. DeMets DL, Pocock SJ, Julian DG. 1999. The agonising negative trend in monitoring of clinical trials. Lancet 354(9194):1983–1988. Deming W. 2000. The New Economics for Industry, Government, Education. Cambridge, MA: MIT Press. DeRenzo EG. 2000. Coercion in the Recruitment and Retention of Human Research Subjects, Pharmaceutical Industry Payments to Physician Investigators, and the Moral Courage of the IRB. IRB 22(2):1–5. Deutsch E and Taupitz J. 2000. Freedom and Control of Biomedical Research. Berlin: Springer. DeYoung K, Nelson D. 2000a, December 21. Firms Find Costa Rica “Special” Place for Trials. The Washington Post. p. A19. DeYoung K, Nelson D. 2000b, December 21. Latin America is Ripe for Trials, and Fraud. The Washington Post. p. A01. DHEW (Department of Health, Education, and Welfare) Secretary’s Task Force on the Compensation of Injured Research Subjects. 1977. Report of the Task Force. Report No. OS-77-003. Bethesda, MD: DHEW. DHHS (Department of Health and Human Services). 1999. A Device Clinical Trials Data Bank—Public Health Need and Impact on Industry. A Report to Congress by the Secretary of Health and Human Services . [Online]. Available: http://www.fda.gov/cdrh/modact/113b.html [accessed June 19, 2002]. DHHS. 2000a. Final PHS Policy for Instruction in the Responsible Conduct of Research. Federal Register 65(236):76647. DHHS. 2000b. Office of Public Health and Science, and the National Institutes of Health, Office of the Director; Statement of Organization, Functions, and Delegations of Authority. Federal Register 65(114):37136–37137. DHHS. 2001a. Draft Interim Guidance: Financial Relationships in Clinical Research: Issues for Institutions, Clinical Investigators, and IRBs to Consider When Dealing With Issues of Financial Interests and Human Subject Protection. [Online]. Available: http://ohrp.osophs.dhhs.gov/nhrpac/mtg12-00/finguid.htm [accessed December 28, 2002].

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants DHHS. 2001b. National Human Research Protections Advisory Committee Charter. [Online]. Available: http://ohrp.osophs.dhhs.gov/nhrpac/charter.htm [accessed May 13, 2002]. DHHS. 2002. 45 CFR 160 and 164: Office of the Secretary; Standards for Privacy of Individually Identifiable Health Information. Federal Register 67(157):53182–53273. Dickersin KD, et al. 2001. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Health Expectations 4(4):213–220. DoD (Department of Defense). 2002. Department of Defense Directive Number 3216.2: Protection of Human Subjects and Adherence to Ethical Standards in DoD-Supported Research. Double Exposure. 2001, December 19. The Washington Post. p. A38. Dresser R. 2001. When Science Offers Salvation: Patient Advocacy and Research Ethics. New York : Oxford University Press. Dretchen K. 2001. The Relationship of IBCs to IRBs and IACUCs: Their Respective Purview, Roles, and Responsibilities. Presentation at the December 7, 2001, meeting, IBCs in a Changing Research Landscape: A Policy Conference, Bethesda, MD. Duke University. 2002, January 9. Press Release. Study Aims to Improve Protection of Research Participants. ECRI (formerly Emergency Care Research Institute). 2002. Should I Enter A Clinical Trial. A Patient Reference Guide for Adults With Serious or Life-Threatening Illness. Washington, DC: American Association of Health Plans. Egger M and Smith GD. 1998. Bias in location and selection of studies. British Medical Journal 316(7124):61-66. Emanuel EJ and Steiner D. 1995. Institutional Conflict of Interest. New England Journal of Medicine 332(4):262–268. Epstein S. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge. USA: University of California Press. Erb T and Sugarman J. 2000. Ethical Issues on Informed Consent and Recruitment for Clinical Trials. Anesthesiology 92(6):1851–1852. Erickson S. 2001. Written comments to the IOM Committee on Assessing the System for Protecting Human Research Participants. Faden RR, Beauchamp TL. 1986. A History and Theory of Informed Consent. New York: Oxford University Press. FDA (Food and Drug Administration). 1996. Protection of Human Subjects; Informed Consent. Federal Register 61(192): 51497–51531. FDA. 1998. Guideline for the Monitoring of Clinical Investigations. [Online]. Available: http://www.fda.gov/ora/compliance_ref/bimo/clinguid.html [accessed February 13, 2002]. FDA. 2001a. Draft Guidance for Clinical Trial Sponsors: On the Establishment and Operation of Clinical Trial Data Monitoring Committees. Federal Register 66(224):58151– 58153. FDA. 2001b. International Conference on Harmonisation; E10 Choice of Control Group in Clinical Trials. Federal Register 66(93):24390–24391. FDA. 2001c. Food and Drug Administration Compliance Program Guidance Manual: Bioresearch Monitoring: Sponsors, Contract Research Organizations, and Monitors. [Online]. Available: http://www.fda.gov/ora/compliance_ref/bimo/7348_810/48-810.pdf [accessed June 12, 2002]. FDA. 2002a. Institutional Review Boards: Requiring Sponsors and Investigators to Inform IRBs of Any Prior IRB Reviews. Federal Register 67(44):10115–10116. FDA. 2002b. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Federal Register 67(105): 37988–37998.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Feussner JR. 2001, March 14. Memorandum: Submission of Research Proposals. Flaherty MP, Nelson D, Stephens J. 2000, December 18. The Body Hunters: Overwhelming the Watchdogs. The Washington Post. p. A01. Flaherty MP and Struck D. 2000, December 22. Life by luck of the draw. The Washington Post. p. A01. Francis L. 1996. IRBs and Conflict of Interest. In: Spece RG, Shimm DS, Buchanan AE, eds. Conflicts of Interest in Clinical Practice and Research. New York: Oxford University Press. Pp. 418–436. Freedman B. 1987. Equipoise and the Ethics of Clinical Research. New England Journal of Medicine 317(3):141–5. Freedman B, Weijer C, Glass K. 1996. Placebo orthodoxy in clinical research. In: Empirical and methodological myths. Journal of Law, Medicine, and Ethics 24(3):243–251. Fureman I, et al. 1997. Evaluation of a Video-Supplement to Informed Consent: Injection Drug Users and Preventive HIV Vaccine Efficacy Trials. AIDS Education and Prevention 9(4):330–341. Gallin JI, ed. 2002. Principles and Practice of Clinical Research. San Diego: Academic Press. Ganter J. 2002. Are Subjects Really Informed? Applied Clinical Trials January 2002:121. GAO (General Accounting Office). 1996. Scientific Research: Continued Vigilance Critical to Protecting Human Subjects. Report No. GAO/HEHS-96-72. Washington, DC: GAO. GAO. 2000. VA Research: Protections for Human Subjects Need to Be Strengthened. Report No. GAO/HEHS-00-155. Washington, DC: GAO. GAO. 2001. Biomedical Research: HHS Direction Needed to Address Financial Conflicts of Interest. Report No. GAO 02-89. Washington, DC: GAO. Gelsinger P. 2000. Jesse’s Intent. Guinea Pig Zero 8:7–17. Getz K, Borfitz D. 2002. Informed Consent: The Consumer’s Guide to the Risks and Benefits of Volunteering for Clinical Trials. Boston, MA: Centerwatch. Gifford AL, et al. 2002. Participation in Research and Access to Experimental Treatments by HIV-Infected Patients. New England Journal of Medicine 346(18):1373–1382. Gillis J. 2002, June 30. A Hospital’s Conflict of Interest: Patients Weren’t Told of Stake in Cancer Drug. The Washington Post. p. A01. Glass K and Lemmens T. 1999. Conflict of Interest and Commercialization of Biomedical Research: What is the Role of Research Ethics Review? In: Caulfield and William-Jones, eds. The Commercialization of Genetic Research. New York: Kluwer Academic/Plenum Publishers. Pp. 79–99. Goldman C. 2000. Paying for University Research Facilities and Administration. Washington, DC: RAND. Gonsalvez G. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Grossman SA, Piantadosi S, Covahey C. 1994. Are Informed Consent Forms That Describe Clinical Oncology Research Readable by Most Patients and their Families? Journal of Clinical Oncology 12(10):2211–2215. Harris Interactive. 2002. There Are Many Reasons Why People Are Reluctant to Participate in Clinical Trials. Health Care News 2(7):1–4. Hayes GJ, Hayes SC, Dykstra T. 1995. A Survey of University Institutional Review Boards: Characteristics, Policies, and Procedures. IRB 17(3):1–6. Heart Special Project Committee. 1967. Heart Special Project Committee: Organization, Review, and Administration of Cooperative Studies (Greenberg Report to the National Advisory Council). Controlled Clinical Trials 9:137–148. Hetherington J, et al. 1989. Retrospective and prospective identification of unpublished controlled trials. Lessons from a survey of controlled trials. Pediatrics 84:374–380.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Hinestrosa C. 2001. What Is Project Lead? Presentation at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Hochhauser M. 1997. Some Overlooked Aspects of Consent Form Readability. IRB 19(5):5–9. Hogg C, Williamson C. 2001. Whose interests do lay people represent? Towards an understanding of the role of lay people as members of committees. Health Expectations 4:2–9. Holm S. 2001. The Danish Research Ethics Committee System—Overview and Critical Assessment. In: NBAC. Ethical and Policy Issues in Research Involving Human Participants. Volume II. Bethesda, MD: NBAC. Pp. F-1–F-25. Hughes EFX. 1988. Perspectives on Quality in American Health Care. Washington, DC: McGraw-Hill Book Company. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharamaceuticals for Human Use). 1996. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice (E6). [Online]. Available: http://www.ich.org/pdfICH/e6.pdf [accessed September 5, 2002]. IOM (Institute of Medicine). 1985. Vaccine Supply and Innovation. Washington, DC: National Academy Press. IOM. 1994. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Washington, DC: National Academy Press. IOM. 1999. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: National Academy Press. IOM. 2000a. Extending Medicare Reimbursement in Clinical Trials. Washington, DC: National Academy Press. IOM. 2000b. To Err Is Human. Washington, DC: National Academy Press. IOM. 2000c. Protecting Data Privacy in Health Services Research. Washington, DC: National Academy Press. IOM. 2001a. Preserving Public Trust: Accreditation and Human Research Participant Protection Programs. Washington, DC: National Academy Press. IOM. 2001b. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press. IOM. 2002. Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC: National Academy Press. IOM and NRC (National Research Council). 2002. Integrity in Scientific Research: Creating an Environment that Promotes Responsible Conduct. Washington, DC: National Academy Press. Jacobs WC. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Jost TS and Davies S. 2002. Medicare and Medicaid Fraud and Abuse. 2002-2003 edition. Minnesota: Westgroup. Juran JM and Godfrey AB, eds. 1999. Juran’s Quality Handbook. New York: McGraw-Hill Professional Publishing. Kahn J, et al. 1998. Changing Claims About Justice in Research. In: Kahn JP, et al. Beyond Consent: Seeking Justice in Research. New York: Oxford University Press. Pp. 1–10. Kass NE and Sugarman J. 1996. Are Research Subjects Adequately Protected? A Review and Discussion of Studies Conducted by the Advisory Committee on Human Radiation Experiments. Kennedy Institute of Ethics Journal 6(3):271–282. Katz J. 1993. Human Experimentation and Human Rights. Saint Louis University Law Journal 38(1):7–54. Kelsey FO. 1991. The Bioresearch Monitoring Program. Food Drug Cosmetic Law Journal 46:59–63.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Kennedy I and Grubb A. 2000. Medical Law. London: Butterworths. King NMP. 1995. Experimental Treatment. Hastings Center Report July/August 1995:6–15. Kirchstein R. 2000. Presentation at the August 15-16, 2000, Conference on Human Subject Protection and Financial Conflicts of Interest, National Institutes of Health, Bethesda, MD. Koski G. 2000. Letter to OHRP Staff. [Online]. Available: http://ohrp.osophs.dhhs.gov/references/ohrpcomp.pdf [accessed April 30, 2002]. LaFraniere S, Flaherty MP, Stephens J. 2000, December 19. The Dilemma: Submit or Suffer. The Washington Post. p. A01. Lehrman S. 2000a. The Gelsinger Story. GeneLetter. [Online]. Available: http://www.geneletter.com/05-01-00/features.gelsinger1.html [accessed February 20, 2001]. Lehrman S. 2000b. The Gelsinger Story: Aftermath. GeneLetter. [Online]. Available: http://www.geneletter.com/06-01-00/features.gelsinger2.html [accessed February 20, 2001]. Lemmens T and Freedman B. 2000. Ethics Review for Sale? Conflict of Interest and Commercial Research Review Boards. Milbank Quarterly 78(4):547–584. Lemmens T and Thompson A. 2001. Noninstitutional Commercial Review Boards in North America: A Critical Appraisal and Comparison with IRBs. IRB 23(2):1–12. Lemonick MD and Goldstein A. 2002. At Your Own Risk. Time Magazine 159(16):46–56. Levine C. 1998. Placebos and HIV: Lessons Learned. Hastings Center Report 28(6):43–48. Levine RJ. 1986. Ethics and Regulation of Clinical Research. New Haven, CT: Yale University Press. Levine RJ. 2001a. Institutional Review Boards: A Crisis in Confidence. Annals of Internal Medicine 134(2):161–163. Levine RJ. 2001b. Human Subjects Protection System: A crisis in confidence. Presentation at the August 21, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Levinsky NG. 2002. Nonfinancial Conflicts of Interest in Research. New England Journal of Medicine 347(10):759–761. Lidz CW, et al. 1983. Barriers to Informed Consent. Annals of Internal Medicine 99(4):539– 543. Lilford R and Jackson J. 1995. Equipoise and the ethics of randomization. Journal of the Royal Society of Medicine 88(10):552–559. Lo B, Wolf LE, Berkeley A. 2000. Conflict-of-interest policies for investigators in clinical trials. New England Journal of Medicine 343(22):1616–20. Love SM. 1995. Dr. Susan Love’s Breast Book. 2nd edition. Reading, MA: Perseus Books. MacQueen KM, et al. 2001. What is Community? An Evidence-Based Definition for Participatory Public Health. American Journal of Public Health 91(12):1929–1938. Manheimer E, Anderson D, Dickersin K. Forthcoming. Identifying ongoing trials online: The need for a comprehensible, comprehensive register. Controlled Clinical Trials. Marwick C. 1998. Compensation for Injured Research Subjects. JAMA 279(23):1854. Marwick C. 2002. Failure to inform public is undermining confidence in clinical trials. BMJ 325:356. Mastroianni A, Kahn J. 2001. Swinging on the Pendulum: Shifting Views of Justice in Human Subjects Research. Hastings Center Report 31(3):21–28. Mather JH, Chief Officer, Office of Research Compliance and Assurance, Department of Veterans Affairs. 2002. Statement on Oversight of Research and Other Issues. Statement at the May 16, 2002, hearing of the Subcommittee on Oversight and Investigations and Subcommittee on Health, Committee on Veterans Affairs, U.S. House of Representatives. McCray AT, Ide NC. 2000. Design and Implementation of a National Clinical Trials Registry. Journal of the American Medical Informatics Association 7(3):313–323.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants McNeilly PJ and Carome M. 2001, July 19. Letter to Edward D. Miller, Chi Van Dang, and Gregory Schaffer Re: Human Subjects Protections Under Multiple Project Assurance (MPA) M-1011. [Online]. Available: http://ohrp.osophs.dhhs.gov/detrm_letrs/jul01a.pdf [accessed June 19, 2002]. Meinert C, Tonascia S. 1986. Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press. Merkatz RB and Summers EI. 1997. Including Women in Clinical Trials: Policy Changes at the Food and Drug Administration. In: Haseltine FP and Jacobson B, eds. Women’s Health Research: A Medical and Policy Primer. Washington, DC: Health Press International. Mitchell A. 2001, December 20. Bush Gives Secrecy Power to Public Health Secretary. The New York Times. p. B6. Moreno J, Caplan AL, Wolpe PR. 1998. Updating protections for human subjects involved in research. Project on Informed Consent, Human Research Ethics Group. JAMA 280(22): 1951–8. Moreno J. 2000. Undue Risk: Secret State Experiments on Humans. New York: WH Freeman & Co. Moreno J. 2001. Goodbye to All That: The End of Moderate Protectionism in Human Subjects Research. Hastings Center Report 31(3):9–17. Moses HI and Martin JB. 2001. Academic Relationships with Industry: A New Model for Biomedical Research. JAMA 285(7):933–935. Murray, T. 1997. Genetic Exceptionalism and “Future Diaries”: Is Genetic Information Different from Other Medical Information? In: Genetic Secrets. Rothstein M, ed. New Haven: Yale University Press. Pp. 60–73. NAMI (National Alliance for the Mentally Ill). 2001. NAMI’s IRB Training Guide for Consumers and Family Members. Arlington, VA: NAMI. NAPBC (National Action Plan on Breast Cancer). 1996. Executive Summary: Model Consent Form for Biological Tissue Banking Focus Group Report. [Online]. Available: http://www.4woman.gov/napbc/napbc/model_consent.htm [accessed June 12, 2002]. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: U.S. Goverment Printing Office. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research . 1978. Report and Recommendations: Institutional Review Boards. Washington, DC: U.S. Goverment Printing Office. NBAC (National Bioethics Advisory Commission). 1998. Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Rockville, MD: NBAC. NBAC. 1999. Research Involving Human Biological Materials: Ethical Issues and Policy Guidance. Volume 1. Rockville, MD: NBAC. NBAC. 2001a. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Rockville, MD: NBAC. NBAC. 2001b. Ethical and Policy Issues in Research Involving Human Participants, Volume I. Bethesda, MD: NBAC. NBAC. 2001c. Federal Agency Survey on Policies and Procedures for the Protection of Human Subjects in Research. In: NBAC. Ethical and Policy Issues in Research Involving Human Participants. Volume II: Commissioned Papers and Staff Analysis. Bethesda, MD: NBAC. Pp. J-1–J-33 NCI (National Cancer Institute, NIH). 1998. Taking Part in Clinical Trials: What Cancer Patients Need to Know. NIH Publication No. 97-4250. NCQA (National Committee for Quality Assurance). 2001. VA Human Research Protection Accreditation Program Accreditation Standards. Washington, DC: NCQA.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Nelson D. 2000, December 18. Drug’s Approval Reveals Cracks in the System. The Washington Post. p. A16. NHRPAC. 2001. NHRPAC Recommendations on HHS’s Draft Interim Guidance on Financial Relationships in Clinical Research. [Online]. Available: http://ohrp.osophs.dhhs.gov/nhrpac/documents/aug01a.pdf [accessed April 4, 2002]. NIH (National Institutes of Health). 1996. Waiver of Informed Consent Requirements in Certain Emergency Research. Federal Register 61(192):51531–51533. NIH. 1998. NIH Policy for Data and Safety Monitoring. [Online]. Available: http://grants.nih.gov/grants/guide/notice-files/not98-084.html [accessed June 18, 2002]. NIH. 2000a. Further Guidance on a Data and Safety Monitoring for Phase I and Phase II Trials. [Online]. Available: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html [accessed January 23, 2002]. NIH. 2000b. Required Education in the Protection of Human Research Participants. OD-00-039. [Online]. Available: http://grants2.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html [accessed June 13, 2002]. NIH. 2001. NIH Training Opportunities: K30 Clinical Research Curriculum Award. [Online]. Available: http://grants1.nih.gov/training/k30.htm [accessed June 13, 2002]. NIH. 2002a. Press Release for the FY 2003 President’s Budget. [Online]. Available: http://www.nih.gov/news/budgetfy2003/2003NIHpresbudget.htm [accessed February 27, 2002]. NIH. 2002b. Human Subjects Research Enhancements Program. OD-02-003. [Online]. Available: http://grants1.nih.gov/grants/guide/rfa-files/RFA-OD-02-003.html [accessed June 13, 2002]. NIH. 2002c. Research on Ethical Issues in Human Studies. PA-02-103. [Online]. Available: http://grants2.nih.gov/grants/guide/pa-files/PA-02-103.html [accessed June 13, 2002]. NIH CC (NIH Clinical Center). 2000. Protomechanics: A Guide to Preparing and Conducting a Clinical Research Study (Figure 7). [Online]. Available: http://www.cc.nih.gov/ccc/protomechanics/ [accessed July 23, 2002]. NIH COPR (NIH Council of Public Representatives). 2001. Human Research Protections in Clinical Trials: A Public Perspective. [Online]. Available: http://public-council.nih.gov/COPRReportOctober2001.asp [accessed November 6, 2001]. NIH CSR (NIH Center for Scientific Review). 2001. Review Procedures for Scientific Review Group Meetings. [Online]. Available: http://www.csr.nih.gov/guidelines/proc.htm [accessed May 2, 2002]. NIH CSR. 2002. New Instructions for Evaluating Grant Applications Involving Human Subjects. Peer Review Notes. January 2002:6-8. NRC (National Research Council). 1996. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press. NRC. 2001. Presentations at the June 28, 2001, meeting of the Panel on Institutional Review Boards, Surveys, and Social Science Research, Washington, DC. NSF (National Science Foundation). 2001. NSF Grant Proposal Guide. [Online]. Available: http://www.nsf.gov/pubs/2002/nsf022/nsf022.pdf [accessed April 11, 2002]. Nuremberg Code. 1949. In: Trials of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law No. 10. Vol. 2, Nuremberg, October 1946–April 1949. Washington, DC: U.S. Government Printing Office. Pp. 181–182. OHRP. 2000. OHRP Compliance Activities: Common Findings and Guidance—Clickable Index. [Online]. Available: http://ohrp.osophs.dhhs.gov/references/findings.pdf [accessed May 1, 2001]. OHRP. 2001. OHRP Compliance Data by Institution, by Determination Letters Issues, and by Site-Visited Institution October 1998 to December 2001. (Unpublished).

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants OHRP. 2002a. Quality Assurance/Quality Improvement Self-Assessment Tool. [Online]. Available: http://ohrp.osophs.dhhs.gov/humansubjects/qip/qatooli.htm [accessed May 13, 2002]. OHRP. 2002b. Quality Improvement Program. [Online]. Available: http://ohrp.osophs.dhhs.gov/humansubjects/qip/qipdesc.pdf [accessed May 7, 2002]. OIG (Office of Inspector General, U.S. Department of Health and Human Services). 1998a. Institutional Review Boards: A Time for Reform. Report No. OEI-01-97-00193. Washington, DC: DHHS OIG. OIG. 1998b. Institutional Review Boards: Promising Approaches. Report No. OEI-01-97-00191. Washington, DC: DHHS OIG. OIG. 1998c. Institutional Review Boards: The Emergence of Independent Boards. Report No. OEI-01-97-00192. Washington, DC: DHHS OIG. OIG. 1998d. Institutional Review Boards: Their Role in Reviewing Approved Research. Report No. OEI-01-97-00190. Washington, DC: DHHS OIG. OIG. 1998e. Low Volume Institutional Review Boards. Report No. OEI-01-97-00194. Washington, DC: DHHS OIG. OIG. 2000a. Protecting Human Research Subjects: Status of Recommendations. Report No. OEI-01-97-00197. Washington, DC: DHHS. OIG. 2000b. Recruiting Human Subjects: Pressures in Industry-Sponsored Clinical Research. Report No. OEI-01-97-00195. Washington, DC: DHHS OIG. OIG. 2000c. Recruiting Human Subjects: Sample Guidelines for Practice. Report No. OEI-01-97-00196. Washington, DC: DHHS OIG. OIG. 2002. Clinical Trial Websites: A Promising Tool to Foster Informed Consent. Report No. OEI-01-97-00198. Washington, DC: DHHS OIG. OPRR (Office for Protection from Research Risks). 1993. Protecting Human Research Subjects: Institutional Review Board Guidebook. Washington, DC: U.S. Government Printing Office. OPRR (Office for Protection from Research Risks) Review Panel. 1999. Report to the Advisory Committee to the Director, NIH From the Office for Protection From Research Risks Review Panel. Rockville, MD: National Institutes of Health. ORCA (Office of Research Compliance and Assurance). 2002. Human Subjects Checklist. [Online]. Available: http://www.va.gov/orca/docs/Human_Subjects_Checklist.doc [accessed August 19, 2002]. Otto MA. 2002a, August 7. Accreditation: NCQA Halts VA Program Inspections to Revise Accreditation Process, Standards. BNA Medical Research Law and Policy Report. Otto MA. 2002b, June 19. NCQA Inspectors Approve Nine VA Centers But Flunk Three, Halt Recruitment at One. BNA Medical Research Law and Policy Report. Otto MA. 2002c, September 18. NHRPAC Charter Lapses; New Group Planned; Former Advisers Suspect Political Motivations. BNA Medical Research Law and Policy Report. Overbey MM. 2001. Written comments to the IOM Committee on Assessing the System for Protecting Human Research Participants. Peckman S. 2001. Local Institutional Review Boards. In: NBAC. Ethical and Policy Issues in Research Involving Human Participants. Volume II. Bethesda, MD: NBAC. Pp. K-1–K-35. Pedrazzani L. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Phelps J. 2000. Presentation at the August 21, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. 1981. Protecting Human Subjects: The Adequacy and Uniformity of Federal Rules and Their Implementation. Washington, DC: U.S. Government Printing Office. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. 1982a. Compensating for Research Injuries: A Report on the Ethical and Legal Implications of Programs to Redress Injuries Caused by Biomedical and Behavioral Research. Washington, DC: U.S. Government Printing Office. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. 1982b. Making Health Care Decisions: A Report on the Ethical and Legal Implications of Informed Consent on the Patient-Practitioner Relationship. Washington, DC: U.S. Government Printing Office. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. 1983. Implementing Human Research Regulations. Washington, DC: U.S. Government Printing Office. Rand Reed K. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Reason J. 1990. Human Error. Cambridge: Cambridge University Press. As quoted in IOM. 2000. To Err is Human. Washington, DC: National Academy Press. Pp. 52. Rettig RA. 2000. The Industrialization of Clinical Research. Health Affairs 19(2):129–146. Roswell RH. Under Secretary for Health, Department of Veterans Affairs. 2002. Non-profit Research Corporations and Educational Foundations and the Department of Veterans Affairs Human Studies Protection Program. Statement at the May 16, 2002, hearing of the Subcommittee on Oversight and Investigations and Subcommittee on Health, Committee on Veterans Affairs, U.S. House of Representatives. Rubin P. 2001. Written comments to the IOM Committee on Assessing the System for Protecting Human Research Participants. Rudder CE. 2001. Written comments to the IOM Committee on Assessing the System for Protecting Human Research Participants. Sackett DL. 1983. On Some Prerequisites for a Successful Clinical Trial. In: Shapiro SH and Louis TA, eds. Clinical Trials: Issues and Approaches. New York: Marcel Dekker. Pp. 65–79. Saunders C, et al. 2001. Foundations of Clinical Research. Wellesley, MA: Center for Clinical Research Practice. Schwartz J. 2001. Oversight of Human Subject Research: The Role of States. In: Ethical and Policy Issues in Research Involving Human Participants, Volume II. Washington, DC: NBAC. Pp. M-1–M-20. Shalala D. 2000. Protecting Research Subjects—What Must Be Done. New England Journal of Medicine 343(11):808–810. Shaywitz DA and Ausiello DA. 2001, July 29. The Necessary Risks of Medical Research. The New York Times. Week in Review, p. 4. Shopes L. 2001. Written comments to the IOM Committee on Assessing the System for Protecting Human Research Participants. Silber T. 2001. Pediatric Research and the Ombudsman. Pediatric Ethicscope 12(1&2):1–5. Softcheck JT. 2002, March 13. NIH offers $28.5 million program to enhance human subjects oversight. Washington Fax. Speers M. 2002a. Presentation at the March 26, 2002, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Speers M. 2002b, June 3. Letter to Robert H. Roswell, Under Secretary for Health, Veterans Health Administration.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Spieler R. 2002, March 5. Secret research must adopt Common Rule human subject protections, bioethicists urge. Washington Fax. Spilker B. 1991. Teaching Courses in Clinical Trial Research Methods. Journal of Clinical Pharmacology 31:496–508. Spilker, B. 2001. An Industry Perspective on Systems for Protecting Human Research Participants. Statement at the August 21, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Stephens J. 2000, December 17. The Body Hunters: As Drug Testing Spreads, Profits and Lives Hang in the Balance. The Washington Post. p. A1. Stolberg SG. 2001, February 11. Children Test New Medicines Despite Doubts. The New York Times. National Desk, p. 1. Stolberg S. 2002, January 8. A Nation Challenged: Steps Against Anthrax; Civilians Are Reluctant to Join U.S. Test of Anthrax Vaccine. The New York Times. p. A13. Sugarman J. 2001. Presentation at the August 21, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Sugarman J, et al. 1999. Empirical Research on Informed Consent: An Annotated Bibliography. Hastings Center Report 29(1):S1–S42. Swankin D. 2001. Presentation at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Taupitz J. 2001. Haftung und Versicherung in der Forschung am Menschen—Landesbericht Deutschland. Unpublished. Temkin O and Temkin L, eds. 1967. Ancient Medicine: Selected Papers of Ludwig Eidelstein. Baltimore, MD: Johns Hopkins University Press. Terry S. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Thacker E. 2002. Conflicts of interest in institutional-based IRBs versus independent IRBs. Research Practitioner 3(1):17–20. Thomson O’Brien MA, et al. 2002. Continuing education meetings and workshops: Effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, Issue 1 . Oxford: Update Software. Tuskegee Syphilis Study Ad Hoc Advisory Panel. 1973. Final Report. Washington, DC: DHEW. U.S. Congress, Senate, Subcommittee on Public Health, Committee on Health, Education, Labor, and Pensions. 2000. Gene Therapy: Is There Oversight to Protect for Patient Safety? 106th Congress. February 2, 2000. VA (U.S. Department of Veterans Affairs). 2002. I’m a Veteran: Should I Participate in Research? (Brochure). Wagner T. 2001. Unpublished Data. The Costs of Operating Institutional Review Boards. Washburn J. 2001, December 30. Informed Consent. The Washington Post. p. W16. Wayne C. 2001. Statement at the November 2, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Weijer C, et al. 2002. The ethics of placebo-controlled trials. New England Journal of Medicine 346:382–383. Weiss R and Nelson D. 1999, December 8. Methods Faulted in Fatal Gene Therapy. The Washington Post. p. A1. Weiss R. 2002, September 17, 2002. HHS Seeks Science Advice to Match Bush Views. The Washington Post. p. A1. Wilson D and Heath D. 2001a, March 11. Patients never knew the full danger of trials they staked their lives on. The Seattle Times. p. A1. Wilson D and Heath D. 2001b, March 12. He saw the test as a violation of “trusting, desperate human beings”. The Seattle Times. p. A1.

OCR for page 217
Responsible Research: A Systems Approach to Protecting Research Participants Wilson D and Heath D. 2001c, March 13. Many patients think that joining testing will help them, but often they’re mistaken. The Seattle Times. p. A6. Wilson D and Heath D. 2001d, March 13. With a year or two to live, woman joined test in which she was misled. The Seattle Times. p. A1. Wilson D and Heath D. 2001e, March 14. He helped create the biotech boom and when it went bust, so did he. The Seattle Times. p. A1. Wilson D and Heath D. 2001f, March 14. No wonder they call the place “Mother Hutch”. The Seattle Times. p. A9. Wilson D and Heath D. 2001g, March 15. The Hutch zealously guards its secrets. The Seattle Times. p. A1. World Medical Association. 2000. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, Revised. Ferney-Voltaire, France: World Medical Association. Wyn Davies H. 2001. The Role of the Private Sector in Protecting Human Research Subjects: A CRO Perspective. Presentation at the August 21, 2001, meeting of the IOM Committee on Assessing the System for Protecting Human Research Participants, Washington, DC. Yamada T. 2001. The Academic-Industry Interface. Presentation at the October 16, 2001, annual meeting of the Institute of Medicine, Washington, DC. Yank V and Rennie D. 2002. Reporting of Informed Consent and Ethics Committee Approval in Clinical Trials. JAMA 287(21):2835–2838. Zieve FJ, McGuire Research Institute. 2002. Statement on Oversight of Research and Other Issues. Statement at the May 16, 2002, hearing of the Subcommittee on Oversight and Investigations and Subcommittee on Health, Committee on Veterans Affairs, U.S. House of Representatives.